SPPAM
IONS icon

Summit Partners Public Asset Management’s Ionis Pharmaceuticals IONS Stock Holding History

Summit Partners Public Asset Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$33.8M Buy
450,000
+150,000
+50% +$11.8M 0.91% 36
2025
Q4 		$23.7M Buy
+300,000
New +$22.6M 0.49% 67

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Summit Partners Public Asset Management's IONS Position: Q1 2026 in Review

Summit Partners Public Asset Management reduced its Ionis Pharmaceuticals (IONS) stake by 4% in Q1 2026, selling an estimated $4.63M and leaving 1,404,033 shares worth $105M. The position accounts for 2.83% of the portfolio, ranked #6.

Summit Partners Public Asset Management first reported a position in IONS in Q3 2025 and has held it in 3 quarters since. The position peaked at $116M in Q4 2025. 494 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

  • Summit Partners Public Asset Management held 1,404,033 shares of Ionis Pharmaceuticals worth $105M as of Q1 2026.
  • Summit Partners Public Asset Management sold 58,673 Ionis Pharmaceuticals shares in Q1 2026, an estimated $4.63M.
  • Ionis Pharmaceuticals made up 2.83% of Summit Partners Public Asset Management's portfolio in Q1 2026, its #6 holding.
  • Summit Partners Public Asset Management first reported a position in Ionis Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Summit Partners Public Asset Management's Ionis Pharmaceuticals position peaked at $116M in Q4 2025.
  • 494 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Summit Partners Public Asset Management's 13F filing for Q1 2026, filed 15 May 2026.